免疫疗法和放射治疗中的DNA损伤反应。
The DNA damage response in immunotherapy and radiation.
作者信息
Samstein Robert M, Riaz Nadeem
机构信息
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
出版信息
Adv Radiat Oncol. 2018 Oct 23;3(4):527-533. doi: 10.1016/j.adro.2018.08.017. eCollection 2018 Oct-Dec.
Abstract
PURPOSE
Deficiencies in DNA damage repair (DDR) and response represent a common alteration in tumors, and exploitation of this feature using therapeutics has become more prominent.
METHODS AND MATERIALS
Recent work has highlighted the important interaction between DDR defects, as well as DDR targeting agents such as radiation and the immunogenicity of the tumor. This relationship emphasizes the potential for combination therapeutics with immune checkpoint inhibitors (ICI). Somatic mutations and DDR defects are some of the strongest predictors of response to ICI.
RESULTS
This review highlights the interplay among DDR pathways, ionizing radiation, and ICI efficacy. The mechanisms of radiation immunogenicity, including the cytosolic DNA sensing cGAS/STING pathways, are also described.
CONCLUSIONS
A greater mechanistic understanding of the complex interaction between the DNA damage response and the immune system will expand the therapeutic potential of immunotherapy for patients with advanced cancer.
摘要
目的
DNA损伤修复（DDR）和反应缺陷是肿瘤中常见的改变，利用治疗手段开发这一特性变得愈发突出。
方法和材料
近期研究强调了DDR缺陷之间的重要相互作用，以及诸如辐射等DDR靶向剂与肿瘤免疫原性之间的相互作用。这种关系凸显了联合使用免疫检查点抑制剂（ICI）进行治疗的潜力。体细胞突变和DDR缺陷是对ICI反应的一些最强预测指标。
结果
本综述强调了DDR通路、电离辐射和ICI疗效之间的相互作用。还描述了辐射免疫原性的机制，包括胞质DNA传感cGAS/STING通路。
结论
对DNA损伤反应与免疫系统之间复杂相互作用的更深入机制理解，将扩大免疫疗法对晚期癌症患者的治疗潜力。
相似文献
1
The DNA damage response in immunotherapy and radiation.免疫疗法和放射治疗中的DNA损伤反应。
Adv Radiat Oncol. 2018 Oct 23;3(4):527-533. doi: 10.1016/j.adro.2018.08.017. eCollection 2018 Oct-Dec.
2
Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy.DNA 损伤反应在免疫和癌症免疫治疗中的功能和分子机制。
Front Immunol. 2021 Dec 14;12:797880. doi: 10.3389/fimmu.2021.797880. eCollection 2021.
3
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.DNA 损伤修复（DDR）系统在免疫检查点抑制剂（ICI）治疗中的作用。
J Exp Clin Cancer Res. 2022 Sep 7;41(1):268. doi: 10.1186/s13046-022-02469-0.
4
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.靶向 DNA 损伤反应和免疫检查点的抗肿瘤治疗。
Int J Mol Sci. 2022 Mar 17;23(6):3238. doi: 10.3390/ijms23063238.
5
Role of DNA repair defects in predicting immunotherapy response.DNA修复缺陷在预测免疫治疗反应中的作用。
Biomark Res. 2020 Jun 29;8:23. doi: 10.1186/s40364-020-00202-7. eCollection 2020.
6
Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy.小儿颅外实体瘤中DNA修复途径的治疗靶点：现状及对免疫治疗的影响
Cancers (Basel). 2024 Apr 25;16(9):1648. doi: 10.3390/cancers16091648.
7
DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy.DNA修复缺陷在癌症中调节免疫反应：分子机制及免疫治疗联合方法
Cancers (Basel). 2023 Mar 6;15(5):1619. doi: 10.3390/cancers15051619.
8
Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy.肿瘤细胞中 DNA 损伤反应缺陷对免疫治疗和放疗反应的影响。
J Med Imaging Radiat Oncol. 2022 Jun;66(4):546-559. doi: 10.1111/1754-9485.13413. Epub 2022 Apr 23.
9
Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.精准肿瘤学和免疫检查点抑制剂时代的DNA损伤修复治疗靶点
J Immunother Precis Oncol. 2022 Dec 2;6(1):31-49. doi: 10.36401/JIPO-22-15. eCollection 2023 Feb.
10
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.靶向 DNA 损伤反应和修复基因增强癌症免疫治疗：原理和临床意义。
Future Oncol. 2020 Aug;16(23):1751-1766. doi: 10.2217/fon-2020-0215. Epub 2020 Jun 15.
引用本文的文献
1
Tumor irradiation induced immunogenic response: the impact of DNA damage induction and misrepair.肿瘤照射诱导的免疫原性反应：DNA损伤诱导和错配修复的影响
Radiat Oncol. 2025 Aug 21;20(1):133. doi: 10.1186/s13014-025-02711-x.
2
Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy.分子靶向治疗在提高（放）化疗疗效中的进展。
Strahlenther Onkol. 2023 Dec;199(12):1091-1109. doi: 10.1007/s00066-023-02064-y. Epub 2023 Apr 11.
3
Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis - The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging.联合使用放射和免疫检查点抑制剂引起的肺炎 - 从不断发展的实验室生物标志物和临床影像学中预测和检测重叠的免疫相关不良反应的挑战。
Neoplasia. 2023 May;39:100892. doi: 10.1016/j.neo.2023.100892. Epub 2023 Apr 1.
4
Molecular and cellular basis of the dose-rate-dependent adverse effects of radiation exposure in animal models. Part II: Hematopoietic system, lung and liver.动物模型中辐射暴露剂量率依赖性不良反应的分子和细胞基础。第二部分：造血系统、肺和肝。
J Radiat Res. 2023 Mar 23;64(2):228-249. doi: 10.1093/jrr/rrad003.
5
Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.PARP抑制剂在癌症免疫治疗中的作用：对免疫激活分子而言可能是盟友，对免疫检查点而言则是敌人
Cancers (Basel). 2022 Nov 16;14(22):5633. doi: 10.3390/cancers14225633.
6
Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy.肿瘤细胞中 DNA 损伤反应缺陷对免疫治疗和放疗反应的影响。
J Med Imaging Radiat Oncol. 2022 Jun;66(4):546-559. doi: 10.1111/1754-9485.13413. Epub 2022 Apr 23.
7
Prevalence and Spectrum of Predisposition Genes With Germline Mutations Among Chinese Patients With Bowel Cancer.中国肠癌患者中携带种系突变的易感基因的患病率及谱系
Front Genet. 2022 Jan 27;12:755629. doi: 10.3389/fgene.2021.755629. eCollection 2021.
8
Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens.靶向质谱法可实现临床生物样本中免疫调节蛋白的多重定量分析。
Front Immunol. 2021 Nov 11;12:765898. doi: 10.3389/fimmu.2021.765898. eCollection 2021.
9
Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy.靶向治疗联合放射治疗的临床和临床前结果
Front Oncol. 2021 Oct 18;11:749496. doi: 10.3389/fonc.2021.749496. eCollection 2021.
10
Interfaces between cellular responses to DNA damage and cancer immunotherapy.细胞对 DNA 损伤反应与癌症免疫治疗的界面。
Genes Dev. 2021 May 1;35(9-10):602-618. doi: 10.1101/gad.348314.121. Epub 2021 Apr 22.
本文引用的文献
1
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.肿瘤突变负担与纳武利尤单抗单药治疗及联合伊匹单抗治疗小细胞肺癌的疗效。
Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3.
2
The Immune Landscape of Cancer.癌症的免疫全景。
Immunity. 2018 Apr 17;48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023. Epub 2018 Apr 5.
3
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.癌症基因组图谱中 DNA 损伤修复缺陷的基因组和分子特征。
Cell Rep. 2018 Apr 3;23(1):239-254.e6. doi: 10.1016/j.celrep.2018.03.076.
4
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.驱动融合及其在人类癌症发生和治疗中的意义。
Cell Rep. 2018 Apr 3;23(1):227-238.e3. doi: 10.1016/j.celrep.2018.03.050.
5
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.DNA 损伤反应和修复基因的改变可作为晚期尿路上皮癌患者接受 PD-1/PD-L1 阻断治疗临床获益的潜在标志物。
J Clin Oncol. 2018 Jun 10;36(17):1685-1694. doi: 10.1200/JCO.2017.75.7740. Epub 2018 Feb 28.
6
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.帕博利珠单抗联合多部位立体定向体部放疗治疗晚期实体瘤患者的安全性和临床疗效。
J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.
7
Chromosomal instability drives metastasis through a cytosolic DNA response.染色体不稳定性通过细胞质 DNA 反应驱动转移。
Nature. 2018 Jan 25;553(7689):467-472. doi: 10.1038/nature25432. Epub 2018 Jan 17.
8
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.采用靶向下一代测序技术对非小细胞肺癌患者进行分析，明确了对抗程序性细胞死亡蛋白 1（PD-1）和抗程序性死亡配体 1（PD-L1）阻断治疗的反应的分子决定因素。
J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16.
9
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.将 DNA 损伤疗法与免疫疗法相结合：欲速则不达。
Br J Cancer. 2018 Feb 6;118(3):312-324. doi: 10.1038/bjc.2017.376. Epub 2017 Nov 9.
10
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer.癌症免疫检查点抑制反应的分子和基因组决定因素。
Annu Rev Med. 2018 Jan 29;69:333-347. doi: 10.1146/annurev-med-060116-022926. Epub 2017 Nov 3.
Zotero 插件